WO2011099721A2 - Composition induisant la maturation de cellules dendritiques - Google Patents

Composition induisant la maturation de cellules dendritiques Download PDF

Info

Publication number
WO2011099721A2
WO2011099721A2 PCT/KR2011/000666 KR2011000666W WO2011099721A2 WO 2011099721 A2 WO2011099721 A2 WO 2011099721A2 KR 2011000666 W KR2011000666 W KR 2011000666W WO 2011099721 A2 WO2011099721 A2 WO 2011099721A2
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
cells
maturation
ifn
present
Prior art date
Application number
PCT/KR2011/000666
Other languages
English (en)
Korean (ko)
Other versions
WO2011099721A3 (fr
Inventor
이제중
홍철이
이준행
이현주
Original Assignee
Lee Je Jung
Hong Cheol Yi
Rhee Joon Haeng
Lee Hyun Ju
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Je Jung, Hong Cheol Yi, Rhee Joon Haeng, Lee Hyun Ju filed Critical Lee Je Jung
Publication of WO2011099721A2 publication Critical patent/WO2011099721A2/fr
Publication of WO2011099721A3 publication Critical patent/WO2011099721A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Definitions

  • the present invention provides a dendritic cell maturation inducing composition containing a bacterial flagellin, tumor necrosis factor, interferon or a mixture thereof as an active ingredient.
  • the method of inducing maturation of immature dendritic cells is characterized by v-FlaB protein derived from Vibrio bulnipicus (Vi & o vw / m jci), tumor necrosis factor, and TNF- ⁇ and interferon as IFN- It is characterized by processing with a mixture of a.
  • the flagellin as a dendritic cell maturation inducing composition may be used in combination with one or more bacteria-derived flagellins.
  • all or part of the flagellin protein may be used, and when a part of flagellin is used, the FlaB protein is preferred.
  • FIG 9 is an absolute diagram present in the matured dendritic cells according to the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une composition induisant la maturation de cellules dendritiques, et en particulier une composition induisant la maturation de cellules dendritiques, contenant de la flagelline bactérienne, du facteur de nécrose des tumeurs, de l'interférone ou des mélanges de ceux-ci comme principes actifs. Comme la composition selon l'invention peut induire efficacement la maturation de cellules dendritiques immatures en cellules dendritiques matures, la composition peut servir de dérivé de maturation d'une cellule dendritique noble et aussi d'agent thérapeutique cellulaire créant de nouvelles conditions pour le traitement des tumeurs.
PCT/KR2011/000666 2010-02-12 2011-01-31 Composition induisant la maturation de cellules dendritiques WO2011099721A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0013088 2010-02-12
KR1020100013088A KR100997753B1 (ko) 2010-02-12 2010-02-12 수지상 세포의 성숙화 유도용 조성물

Publications (2)

Publication Number Publication Date
WO2011099721A2 true WO2011099721A2 (fr) 2011-08-18
WO2011099721A3 WO2011099721A3 (fr) 2011-12-15

Family

ID=43512265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000666 WO2011099721A2 (fr) 2010-02-12 2011-01-31 Composition induisant la maturation de cellules dendritiques

Country Status (2)

Country Link
KR (1) KR100997753B1 (fr)
WO (1) WO2011099721A2 (fr)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HERTZ ET AL.: 'Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2' THE JOURNAL OF IMMUNOLOGY vol. 166, 2001, pages 2444 - 2450 *
JEONG ET AL.: 'A bacterial Flagellin, Vibrio vulnificus FlaB, induces human dendritic cell maturation' JOURNAL OF BACTERIOLOGY AND VIROLOGY vol. 35, no. 3, 2005, pages 209 - 216 *
MEANS ET AL.: 'The Toll-like receptor 5 stimulus bacterial Flagellin induces maturation and chemokine production in human dendritic cells' THE JOURNAL OF IMMUNOLOGY vol. 170, 2003, pages 5165 - 5175 *
SOUSA-CANAVEZ ET AL.: 'Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: A promising approach for the treatment of prostrate cancer' GENETIC VACCINES THERAPY vol. 6, 2008, pages 1 - 7 *

Also Published As

Publication number Publication date
WO2011099721A3 (fr) 2011-12-15
KR100997753B1 (ko) 2010-12-02

Similar Documents

Publication Publication Date Title
Wherry et al. Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli
Linehan et al. CD25+ CD4+ regulatory T-cells in cancer
Romano et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo
Pan et al. Interferon-γ is an autocrine mediator for dendritic cell maturation
Frassanito et al. Deregulated cytokine network and defective Th1 immune response in multiple myeloma
Zhang et al. Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice
Lum et al. In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages
Dey et al. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana
CA2700618A1 (fr) Inhibition de l'activation et de la potentialisation des lymphocytes t regulateurs entrainees par une cellule dendritique de reponses des lymphocytes t specifiques d'un antigene de tumeur par l'interleukine-15 et un inhibiteur de la kinase map
Lu et al. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection
Cong et al. Generation of antigen-specific, Foxp3-expressing CD4+ regulatory T cells by inhibition of APC proteosome function
KR101415039B1 (ko) 자기유래 활성화 림프구의 대량 증식을 위한 배지 조성물 및 배양방법
JPH11290068A (ja) ナチュラルキラ―（ｎｋ）細胞の活性化方法及びその実施手段
Gilliet et al. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
WO2012110596A1 (fr) Protéine de fusion pour le traitement de réactions immunologiques ou allergiques
Wang et al. Nocardia rubra cell-wall skeleton promotes CD4+ T cell activation and drives Th1 immune response
WO2013180481A1 (fr) Composition pour la maturation de cellules dendritiques, et procédé pour la préparation de cellules dendritiques spécifiques d'un antigène l'utilisant
Fujimura et al. A synthetic NOD2 agonist, muramyl dipeptide (MDP)-Lys (L18) and IFN-β synergistically induce dendritic cell maturation with augmented IL-12 production and suppress melanoma growth
Lin et al. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity
KR101568323B1 (ko) 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
Inoue et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
Detournay et al. IL-6 produced by type I IFN DC controls IFN-γ production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells
Ren et al. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma
Kim et al. Lack of transglutaminase 2 diminished T‐cell responses in mice
KR101221590B1 (ko) 결핵균의 ｒｖ0351 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742413

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21-11-2012)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 21.11.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 11742413

Country of ref document: EP

Kind code of ref document: A2